Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2010

01.08.2010 | Preclinical Study

Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells

verfasst von: Tisheeka R. Graham, Rami Yacoub, LaTonia Taliaferro-Smith, Adeboye O. Osunkoya, Valerie A. Odero-Marah, Tongrui Liu, K. Sean Kimbro, Dipali Sharma, Ruth M. O’Regan

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Zinc-finger enhancer binding protein (ZEB1) is a transcription factor involved in the progression of cancer primarily through promoting epithelial to mesenchymal transition (EMT). ZEB1 represses the expression of E-cadherin by binding to E-box sequences in the promoter, thus decreasing epithelial differentiation. We show that ZEB1 and androgen receptor (AR) cross-talk in triple negative breast cancer cell lines. Chromatin immunoprecipitation analysis demonstrates that ZEB1 binds directly to the E-box located in the AR promoter. ZEB1 suppression by stably transfecting shRNA in a triple negative breast cancer cell line resulted in a decrease of AR mRNA, protein, and AR downstream targets. ZEB1 knockdown in triple negative breast cancer cells sensitized the cells to bicalutamide by reducing migration compared to the control cells. Conversely, blockade of AR signaling with bicalutamide resulted in a suppression of ZEB1 protein expression in two triple negative breast cancer cell lines. Furthermore, using a breast cancer tissue microarray, a majority of triple negative breast cancers exhibit positive staining for both ZEB1 and AR. Taken together, these results indicate that ZEB1 and AR regulate each other to promote cell migration in triple negative breast cancer cells.
Literatur
1.
Zurück zum Zitat Brys M, Wojcik M, Makowska H, Krajewska W (2002) Androgen receptor status in female breast cancer: RT-PCR and western blot studies. J Cancer Res Clin Oncol 128:85–90CrossRefPubMed Brys M, Wojcik M, Makowska H, Krajewska W (2002) Androgen receptor status in female breast cancer: RT-PCR and western blot studies. J Cancer Res Clin Oncol 128:85–90CrossRefPubMed
2.
Zurück zum Zitat Davidson N, Lippman M (1989) The role of estrogens in growth regulation of breast cancer. Crit Rev Oncog 1:89–111PubMed Davidson N, Lippman M (1989) The role of estrogens in growth regulation of breast cancer. Crit Rev Oncog 1:89–111PubMed
3.
Zurück zum Zitat Platet N, Cathiard A, Gleizes M, Garcia M (2004) Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 51:55–67CrossRefPubMed Platet N, Cathiard A, Gleizes M, Garcia M (2004) Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 51:55–67CrossRefPubMed
4.
Zurück zum Zitat Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF et al (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years of adjuvant treatment for breast cancer. Lancet 365:60–62CrossRefPubMed Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF et al (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years of adjuvant treatment for breast cancer. Lancet 365:60–62CrossRefPubMed
5.
Zurück zum Zitat Isola J (1993) Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 170:31–35CrossRefPubMed Isola J (1993) Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 170:31–35CrossRefPubMed
6.
Zurück zum Zitat Diaz-Chico B, Rodriguez F, Gonzalez A, Ramirez R, Bilbao C et al (2007) Androgens and androgen receptors in breast cancer. Steroid Biochem Mol Biol 105:1–15CrossRef Diaz-Chico B, Rodriguez F, Gonzalez A, Ramirez R, Bilbao C et al (2007) Androgens and androgen receptors in breast cancer. Steroid Biochem Mol Biol 105:1–15CrossRef
7.
Zurück zum Zitat Birrell S, Hall R, Tilley W (1998) Role of androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia 3:95–103CrossRefPubMed Birrell S, Hall R, Tilley W (1998) Role of androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia 3:95–103CrossRefPubMed
8.
Zurück zum Zitat Zhu X, Li H, Liu JP, Funder JW (1999) Androgen stimulates mitogen-activated protein kinase in human breast cancer cells. Mol Cell Endocrinol 152:199–206CrossRefPubMed Zhu X, Li H, Liu JP, Funder JW (1999) Androgen stimulates mitogen-activated protein kinase in human breast cancer cells. Mol Cell Endocrinol 152:199–206CrossRefPubMed
9.
Zurück zum Zitat Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, Tilley WD (1995) Androgens induced divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 52:459–467CrossRefPubMed Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, Tilley WD (1995) Androgens induced divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 52:459–467CrossRefPubMed
10.
Zurück zum Zitat Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald W et al (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25:3994–4008CrossRefPubMed Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald W et al (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25:3994–4008CrossRefPubMed
11.
Zurück zum Zitat Wong YC, Xie B (2001) The role of androgens I mammary carcinogenesis. Ital J Anat Embryol 106:111–115PubMed Wong YC, Xie B (2001) The role of androgens I mammary carcinogenesis. Ital J Anat Embryol 106:111–115PubMed
12.
Zurück zum Zitat Boccuzzi G, Tamagno E, Brignardello E et al (1995) Growth inhibition of DMBA-induced rat mammary carcinomas by the antiandrogen flutamide. J Cancer Res Clin Oncol 121:150–154CrossRefPubMed Boccuzzi G, Tamagno E, Brignardello E et al (1995) Growth inhibition of DMBA-induced rat mammary carcinomas by the antiandrogen flutamide. J Cancer Res Clin Oncol 121:150–154CrossRefPubMed
13.
Zurück zum Zitat Naderi A, Hughes-Davies L (2008) A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 10:542–548PubMed Naderi A, Hughes-Davies L (2008) A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 10:542–548PubMed
14.
Zurück zum Zitat Eger A, Aigner K, Sonderegger S et al (2005) Delta EF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 24:2375–2385CrossRefPubMed Eger A, Aigner K, Sonderegger S et al (2005) Delta EF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 24:2375–2385CrossRefPubMed
15.
Zurück zum Zitat Ohira T, Gemmill R, Ferguson K et al (2003) WNT7a induces E-cadherin in lung cancer cells. PNAS 100:10429–10434CrossRefPubMed Ohira T, Gemmill R, Ferguson K et al (2003) WNT7a induces E-cadherin in lung cancer cells. PNAS 100:10429–10434CrossRefPubMed
16.
Zurück zum Zitat Spaderna S, Schmalhofer O, Hlubek F, Berx G, Eger A, Merkel S et al (2006) A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 131:830–840CrossRefPubMed Spaderna S, Schmalhofer O, Hlubek F, Berx G, Eger A, Merkel S et al (2006) A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 131:830–840CrossRefPubMed
17.
Zurück zum Zitat Vincent-Salomon A, Theiry JP (2003) Epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res 5:101–106CrossRefPubMed Vincent-Salomon A, Theiry JP (2003) Epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res 5:101–106CrossRefPubMed
18.
Zurück zum Zitat Chua H, Bhat-Nakshatri P, Clare S, Morimiya A, Badve S, Nakshatri H (2007) NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB1 and ZEB2. Oncogene 26:711–724 Chua H, Bhat-Nakshatri P, Clare S, Morimiya A, Badve S, Nakshatri H (2007) NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB1 and ZEB2. Oncogene 26:711–724
19.
Zurück zum Zitat Graham TR, Zhau H, Odero-Marah V, Osunkoya A, Kimbro K et al (2008) Insulin-like growth factor-I-dependent upregulation of ZEB1 drives epithelial to mesenchymal transition in human prostate cancer cells. Cancer Res 68:2479–2488CrossRefPubMed Graham TR, Zhau H, Odero-Marah V, Osunkoya A, Kimbro K et al (2008) Insulin-like growth factor-I-dependent upregulation of ZEB1 drives epithelial to mesenchymal transition in human prostate cancer cells. Cancer Res 68:2479–2488CrossRefPubMed
20.
Zurück zum Zitat Postigo A, Dean D (1997) ZEB, a vertebrate homolog of Drosophila Zfh-1, is a negative regulator of muscle differentiation. EMBO J 16:3935–3943CrossRefPubMed Postigo A, Dean D (1997) ZEB, a vertebrate homolog of Drosophila Zfh-1, is a negative regulator of muscle differentiation. EMBO J 16:3935–3943CrossRefPubMed
21.
Zurück zum Zitat Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, Bauer K et al (2008) The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 68:537–544CrossRefPubMed Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, Bauer K et al (2008) The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 68:537–544CrossRefPubMed
22.
Zurück zum Zitat Spoelstra N, Manning N, Higashi Y, Darling D, Singh M, Shroyer K et al (2006) The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res 66:3893–3902CrossRefPubMed Spoelstra N, Manning N, Higashi Y, Darling D, Singh M, Shroyer K et al (2006) The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res 66:3893–3902CrossRefPubMed
23.
Zurück zum Zitat Hope I, Mahadevan S, Struhl K (1998) Structural and functional characterization of the short acidic transcriptional activation domain of yeast GCN4 protein. Nature 333:635–640CrossRef Hope I, Mahadevan S, Struhl K (1998) Structural and functional characterization of the short acidic transcriptional activation domain of yeast GCN4 protein. Nature 333:635–640CrossRef
24.
Zurück zum Zitat Seipel K, Georgiev O, Schaffner W (1992) Different activation domains stimulate transcription from remote (“enhancer”) and proximal (“promoter”) positions. EMBO J 11:4961–4968PubMed Seipel K, Georgiev O, Schaffner W (1992) Different activation domains stimulate transcription from remote (“enhancer”) and proximal (“promoter”) positions. EMBO J 11:4961–4968PubMed
25.
Zurück zum Zitat Aigner K, Dampier B, Descovich L et al (2007) The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 26:1–10CrossRef Aigner K, Dampier B, Descovich L et al (2007) The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 26:1–10CrossRef
26.
Zurück zum Zitat Wang F, Sloss C, Zhang X, Lee SW, Cusack J (2007) Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells. Cancer Res 67:8486–8493CrossRefPubMed Wang F, Sloss C, Zhang X, Lee SW, Cusack J (2007) Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells. Cancer Res 67:8486–8493CrossRefPubMed
27.
Zurück zum Zitat Sharma D, Fondell JD. (2002) Ordered recruitment of histone acetyltransferases and the TRAP/mediator complex to thyroid hormone-responsive promoters in vivo. Proc Natl Acad Sci 99:7394–7399CrossRef Sharma D, Fondell JD. (2002) Ordered recruitment of histone acetyltransferases and the TRAP/mediator complex to thyroid hormone-responsive promoters in vivo. Proc Natl Acad Sci 99:7394–7399CrossRef
28.
Zurück zum Zitat Hall R, Clements J, Birrell S, Tilley W (1998) Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. Br J Cancer 78:360–365PubMed Hall R, Clements J, Birrell S, Tilley W (1998) Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. Br J Cancer 78:360–365PubMed
29.
Zurück zum Zitat DiMonaco M, Brignardello E, Leonardi L, Gatto V, Bocuzzi G (1995) Inhibitory effect of hydroxyflutamide plus tamoxifen on oestradiol-induced growth of MCF-7 breast cancer cells. J Cancer Res Clin Oncol 121:710–714CrossRef DiMonaco M, Brignardello E, Leonardi L, Gatto V, Bocuzzi G (1995) Inhibitory effect of hydroxyflutamide plus tamoxifen on oestradiol-induced growth of MCF-7 breast cancer cells. J Cancer Res Clin Oncol 121:710–714CrossRef
30.
Zurück zum Zitat Richer J, Jacobsen B, Manning N, Abel M, Wolf D, Horwitz K (2002) Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 277:5209–5218CrossRefPubMed Richer J, Jacobsen B, Manning N, Abel M, Wolf D, Horwitz K (2002) Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 277:5209–5218CrossRefPubMed
31.
Zurück zum Zitat Chamberlain EM, Sanders MM (1999) Identification of the novel player deltaEF1 in estrogen transcriptional cascades. Mol Cell Biol 19:3600–3609PubMed Chamberlain EM, Sanders MM (1999) Identification of the novel player deltaEF1 in estrogen transcriptional cascades. Mol Cell Biol 19:3600–3609PubMed
32.
Zurück zum Zitat Singh M, Spoelstra N, Jean A, Howe E, Torkko K, Clark H, Darling D, Shroyer K, Horwitz K, Broaddus R, Richer J (2008) ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol 21:1–12CrossRef Singh M, Spoelstra N, Jean A, Howe E, Torkko K, Clark H, Darling D, Shroyer K, Horwitz K, Broaddus R, Richer J (2008) ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol 21:1–12CrossRef
33.
Zurück zum Zitat Dillner N, Sanders M (2004) Transcriptional activation by the zinc-finger homeodomain protein delta EF1 in estrogen signaling cascades. DNA Cell Biol 23:25–34CrossRefPubMed Dillner N, Sanders M (2004) Transcriptional activation by the zinc-finger homeodomain protein delta EF1 in estrogen signaling cascades. DNA Cell Biol 23:25–34CrossRefPubMed
34.
Zurück zum Zitat Lazarova DL, Bordonaro M, Sartorelli AC (2001) Transcriptional regulation of the vitamin D3 receptor gene by ZEB. Cell Growth Differ 12:319–326PubMed Lazarova DL, Bordonaro M, Sartorelli AC (2001) Transcriptional regulation of the vitamin D3 receptor gene by ZEB. Cell Growth Differ 12:319–326PubMed
35.
Zurück zum Zitat Sekido R, Murai K, Funashashi J, Kamachi Y, Fujisawa A (1997) Two mechanisms in the action of repressor δEF1: binding site competition with an activator and active repression. Genes Cells 2:771–783CrossRefPubMed Sekido R, Murai K, Funashashi J, Kamachi Y, Fujisawa A (1997) Two mechanisms in the action of repressor δEF1: binding site competition with an activator and active repression. Genes Cells 2:771–783CrossRefPubMed
36.
Zurück zum Zitat Anose B, LaGoo L, Schwendinger J (2008) Characterization of androgen regulation of ZEB and PSA in 22RV1 prostate cancer cells. Adv Exp Med Biol 617:541–546CrossRefPubMed Anose B, LaGoo L, Schwendinger J (2008) Characterization of androgen regulation of ZEB and PSA in 22RV1 prostate cancer cells. Adv Exp Med Biol 617:541–546CrossRefPubMed
Metadaten
Titel
Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells
verfasst von
Tisheeka R. Graham
Rami Yacoub
LaTonia Taliaferro-Smith
Adeboye O. Osunkoya
Valerie A. Odero-Marah
Tongrui Liu
K. Sean Kimbro
Dipali Sharma
Ruth M. O’Regan
Publikationsdatum
01.08.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0623-7

Weitere Artikel der Ausgabe 1/2010

Breast Cancer Research and Treatment 1/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.